ERIS.NS Profit & Loss
Eris Lifesciences Ltd.
Profit & Loss Balance Sheet Cash Flow
Profit & Loss · 4 years on file
(FY2022-23 to FY2025-26)
· fetched 2026-08-24 01:34
| Line item | FY2022-23 | FY2023-24 | FY2024-25 | FY2025-26 | Source (XBRL element) |
|---|---|---|---|---|---|
| Revenue from Operations | ₹1,685.15 Cr. | ₹2,009.14 Cr. | ₹2,893.64 Cr. | ₹3,129.42 Cr. | RevenueFromOperations |
| Gross Revenue (incl. inter-segment) | N/A | N/A | N/A | N/A | SegmentRevenueFromOperations |
| Other Income | ₹11.15 Cr. | ₹23.82 Cr. | ₹18.36 Cr. | ₹7.75 Cr. | OtherIncome |
| Total Income | ₹1,696.30 Cr. | ₹2,032.96 Cr. | ₹2,912.00 Cr. | ₹3,137.17 Cr. | Income |
| Cost of Materials Consumed | ₹142.20 Cr. | ₹177.81 Cr. | ₹276.34 Cr. | ₹326.65 Cr. | CostOfMaterialsConsumed |
| Purchases of Stock-in-Trade | ₹206.33 Cr. | ₹201.51 Cr. | ₹473.12 Cr. | ₹490.56 Cr. | PurchasesOfStockInTrade |
| Changes in Inventories | ₹3.82 Cr. | ₹0.72 Cr. | ₹-35.47 Cr. | ₹-21.61 Cr. | ChangesInInventoriesOfFinishedGoodsWorkInProgressAndStockInTrade |
| Employee Benefit Expense | ₹346.16 Cr. | ₹403.81 Cr. | ₹505.09 Cr. | ₹556.81 Cr. | EmployeeBenefitExpense |
| Finance Costs | ₹26.17 Cr. | ₹84.80 Cr. | ₹231.29 Cr. | ₹192.67 Cr. | FinanceCosts |
| Depreciation and Amortisation | ₹117.09 Cr. | ₹182.60 Cr. | ₹315.46 Cr. | ₹279.50 Cr. | DepreciationDepletionAndAmortisationExpense |
| Other Expenses | ₹449.90 Cr. | ₹550.45 Cr. | ₹657.36 Cr. | ₹656.90 Cr. | OtherExpenses |
| Total Expenses | ₹1,291.66 Cr. | ₹1,601.72 Cr. | ₹2,423.19 Cr. | ₹2,481.48 Cr. | Expenses |
| Profit Before Exceptional Items and Tax | ₹404.64 Cr. | ₹431.24 Cr. | ₹488.81 Cr. | ₹655.69 Cr. | ProfitBeforeExceptionalItemsAndTax |
| Exceptional Items | ₹0.00 Cr. | ₹0.00 Cr. | ₹0.00 Cr. | ₹-17.24 Cr. | ExceptionalItemsBeforeTax |
| Profit Before Tax | ₹404.64 Cr. | ₹431.24 Cr. | ₹488.81 Cr. | ₹638.45 Cr. | ProfitBeforeTax |
| Tax Expense | ₹30.48 Cr. | ₹34.19 Cr. | ₹114.20 Cr. | ₹-8.97 Cr. | TaxExpense |
| Net Profit (incl. minority interest) | ₹374.16 Cr. | ₹397.05 Cr. | ₹374.67 Cr. | ₹647.51 Cr. | ProfitLossForPeriod |
| Net Profit (to shareholders) | ₹382.16 Cr. | ₹391.98 Cr. | ₹351.84 Cr. | ₹619.52 Cr. | ProfitOrLossAttributableToOwnersOfParent |
| Basic EPS | ₹28.10 | ₹28.82 | ₹25.85 | ₹45.33 | BasicEarningsLossPerShareFromContinuingAndDiscontinuedOperations |
| Diluted EPS | ₹28.07 | ₹28.79 | ₹25.81 | ₹45.26 | DilutedEarningsLossPerShareFromContinuingAndDiscontinuedOperations |
Every figure above is the exact value of the named XBRL element from ERIS.NS's cached filing for that year — nothing here is estimated or backfilled. A company shows one column per year StockProof actually has data for — never padded with blank years. Rows shown as N/A are genuinely not disclosed under that year's filing format (see peer comparison for how other Healthcare companies compare).